Anemia in HIV-infected patients receiving highly active antiretroviral therapy
Anemia in HIV-infected patients receiving highly active antiretroviral therapy
复制标题
DOI：
10.1097/00042560-200201010-00007
复制
发表时间：
2002-01-01
期刊：
影响因子：
--
通讯作者：
Forney, D
中科院分区：
文献类型：
--
作者：
Moore, RD;Forney, D
背景：贫血在HIV感染中很常见，尤其是在晚期疾病状态中。我们希望确定如何高活性抗逆转录病毒疗法（HAART）和其他因素影响的血红蛋白水平在HIV infection.Methods：我们分析了905例患者接受护理后，在巴尔的摩，马里兰州约翰霍普金斯1996年7月1日的数据。对接受和未接受HAART治疗的患者在基线和1年随访期间获得的血红蛋白水平进行分析。HAART和其他人口统计学和临床因素的使用进行了examined.Results：11 pet-cent的患者有血红蛋白计数14 g/dL的基线前HAART开始。在一年的随访中，42%的患者使用HAART与血红蛋白水平>14 g/dL相关，而不考虑是否使用齐多夫定作为HAART方案的一部分，相比之下，31%的患者没有使用HAART。在多变量分析中，HAART的使用是密切相关的，没有贫血在一年的后续行动，调整患者性别，种族，注射吸毒史，基线CD 4和HIV-1 RNA水平，和贫血treatment.Conclusions：HAART是一种有效的治疗艾滋病病毒感染的贫血。在接受HAART治疗期间仍有症状性贫血的患者可能需要额外的干预。
Background: Anemia is common in HIV infection, particularly in advanced disease states. We Wished to determine how highly active antiretroviral therapy (HAART) and other factors affected the level of hemoglobin in HIV infection.Methods: We analyzed data from 905 patients receiving care at Johns Hopkins in Baltimore, Maryland after July 1, 1996. Analyses were done of hemoglobin levels obtained at baseline and during I year of follow-up in patients who received and did not receive a HAART regimen. Use of HAART and other demographic and clinical factors were examined.Results: Eleven pet-cent of patients had a hemoglobin count 14 g/dL at baseline before HAART was started. During I year of follow-up, use of HAART was associated with a hemoglobin levels >14 g/dL in 42% of patients, irrespective of use of zidovudine as part of HAART regimen, compared With 31% of patients Who did not use HAART. In multivariate analysis, use of HAART was strongly associated with not having anemia during I year of follow-up, adjusting for patient gender, race, injection drug use history, baseline CD4 and HIV-1 RNA levels, and anemia treatments.Conclusions: HAART is an effective treatment of the anemia of HIV infection. Patients Who continue to have symptomatic anemia While receiving HAART may need additional intervention.